Skip to main content
News

Giredestrant Plus Everolimus Reduces Progression Risk by 62% in ESR1-Mutated Advanced Breast Cancer

Edited by 

Clinical Summary:

  • Design/Population: The open-label, phase 3 evERA Breast Cancer trial evaluated giredestrant plus everolimus versus standard endocrine therapy plus everolimus in patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer who experienced disease progression or recurrence after CDK4/6 inhibitor-based endocrine therapy. 
  • Key Outcomes: Giredestrant plus everolimus significantly improved progression-free survival in patients with ESR1-mutated tumors and in the overall study population, reducing the hazard of progression or death by 62% and 44%, respectively. The incidence of adverse events were similar between treatment groups.
  • Clinical Relevance: These findings support giredestrant plus everolimus as an endocrine-based treatment option following CDK4/6 inhibitor therapy, with the greatest benefit observed in patients with ESR1-mutated disease, reinforcing the importance of molecular testing to guide treatment selection. 

Results from the phase 3 evERA Breast Cancer trial demonstrated that giredestrant plus everolimus significantly improved progression-free survival (PFS) compared with standard endocrine therapy plus everolimus in patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer previously treated with a CDK4/6 inhibitor, with the greatest benefit observed among patients with ESR1-mutated tumors. 

In this open-label trial, 373 patients who experienced disease progression or recurrence following CDK4/6 inhibitor-based endocrine therapy were randomized 1:1 to receive either giredestrant plus everolimus (n = 183) or standard endocrine therapy plus everolimus (n = 190). Standard endocrine therapy consisted of exemestane, fulvestrant, or tamoxifen.

The primary end point was investigator-assessed PFS, evaluated sequentially in patients with ESR1-mutated tumors (n = 207) and subsequently in the overall study population. A key secondary end point was safety. 

Among patients with ESR1-mutated disease, median PFS was 10 months in the giredestrant plus everolimus arm and 5.5 months in the standard endocrine therapy plus everolimus arm, reducing the hazard of disease progression or death by 62% (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.27 to 0.54; P < .001).

A significant PFS benefit was also observed in the overall study population. Median PFS was 8.8 months in the giredestrant plus everolimus arm and 5.5 months in the standard endocrine therapy plus everolimus arm, corresponding to a 44% reduction in the hazard of disease progression or death (HR, 0.56; 95% CI, 0.44 to 0.71; P < .001).

Adverse events occurred in 98.9% of patients receiving giredestrant plus everolimus and 96.8% of patients receiving standard endocrine therapy plus everolimus. The most common events were stomatitis (47.3% vs48.9%), diarrhea (26.9% vs 22.6%), and anemia (23.6% vs 21%). 

These findings demonstrate that combining estrogen receptor antagonism with mTOR inhibition improved disease control compared with standard endocrine therapy plus everolimus, with the largest observed benefit among patients harboring ESR1 mutations.


Source:

Mayer EL, Tolaney SM, Martín M, et al. Giredestrant plus everolimus in advanced breast cancer. N Engl J Med. Published online: September 30, 2026. doi: 10.1056/nejmoa2602457

© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of LL&M, Oncology Learning Network or HMP Global, their employees, and affiliates.